ES2325431B1 - Secuencia de nucleotidos y peptidos gse 24.2 de la disquerina inductores de la actividad telomerasa, procedimiento de obtencion, composiciones terapeuticas y sus aplicaciones. - Google Patents
Secuencia de nucleotidos y peptidos gse 24.2 de la disquerina inductores de la actividad telomerasa, procedimiento de obtencion, composiciones terapeuticas y sus aplicaciones. Download PDFInfo
- Publication number
- ES2325431B1 ES2325431B1 ES200502511A ES200502511A ES2325431B1 ES 2325431 B1 ES2325431 B1 ES 2325431B1 ES 200502511 A ES200502511 A ES 200502511A ES 200502511 A ES200502511 A ES 200502511A ES 2325431 B1 ES2325431 B1 ES 2325431B1
- Authority
- ES
- Spain
- Prior art keywords
- baselineskip
- nucleotide sequence
- sequence
- gse
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000000694 effects Effects 0.000 title claims abstract description 132
- 108010017842 Telomerase Proteins 0.000 title claims abstract description 121
- 239000002773 nucleotide Substances 0.000 title claims abstract description 85
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 38
- 238000000034 method Methods 0.000 title claims abstract description 29
- 239000000203 mixture Substances 0.000 title claims abstract description 24
- 230000001225 therapeutic effect Effects 0.000 title abstract description 12
- 102000004196 processed proteins & peptides Human genes 0.000 title description 7
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 83
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 40
- 239000012634 fragment Substances 0.000 claims abstract description 35
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 33
- 238000011282 treatment Methods 0.000 claims abstract description 28
- 201000010099 disease Diseases 0.000 claims abstract description 23
- 230000032683 aging Effects 0.000 claims abstract description 14
- 206010010356 Congenital anomaly Diseases 0.000 claims abstract description 9
- 230000001133 acceleration Effects 0.000 claims abstract description 7
- 230000004770 neurodegeneration Effects 0.000 claims abstract description 6
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract description 6
- 241000282414 Homo sapiens Species 0.000 claims description 41
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 30
- 206010062759 Congenital dyskeratosis Diseases 0.000 claims description 28
- 238000010276 construction Methods 0.000 claims description 22
- 239000013604 expression vector Substances 0.000 claims description 19
- 230000002068 genetic effect Effects 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 16
- 230000004075 alteration Effects 0.000 claims description 15
- 239000002299 complementary DNA Substances 0.000 claims description 14
- 239000013612 plasmid Substances 0.000 claims description 13
- 208000035475 disorder Diseases 0.000 claims description 10
- 150000001413 amino acids Chemical class 0.000 claims description 9
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 9
- 238000011084 recovery Methods 0.000 claims description 9
- 230000007170 pathology Effects 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 230000009467 reduction Effects 0.000 claims description 6
- 206010008025 Cerebellar ataxia Diseases 0.000 claims description 5
- 208000018737 Parkinson disease Diseases 0.000 claims description 5
- 210000001766 X chromosome Anatomy 0.000 claims description 5
- 108020004999 messenger RNA Proteins 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 206010028570 Myelopathy Diseases 0.000 claims description 3
- 210000001236 prokaryotic cell Anatomy 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 1
- 210000002257 embryonic structure Anatomy 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 abstract description 50
- 102100031249 H/ACA ribonucleoprotein complex subunit DKC1 Human genes 0.000 abstract description 42
- 239000013598 vector Substances 0.000 abstract description 40
- 101710167047 H/ACA ribonucleoprotein complex subunit DKC1 Proteins 0.000 abstract description 39
- 102000004169 proteins and genes Human genes 0.000 abstract description 37
- 150000001875 compounds Chemical class 0.000 abstract description 26
- 239000012190 activator Substances 0.000 abstract description 6
- 239000000411 inducer Substances 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 151
- 101710137284 Protein STPG4 Proteins 0.000 description 95
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 58
- 229960004316 cisplatin Drugs 0.000 description 58
- 230000014509 gene expression Effects 0.000 description 51
- 239000003112 inhibitor Substances 0.000 description 19
- 238000001890 transfection Methods 0.000 description 15
- 108020004414 DNA Proteins 0.000 description 14
- 230000035899 viability Effects 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 13
- 230000005764 inhibitory process Effects 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 11
- 108060001084 Luciferase Proteins 0.000 description 9
- 239000005089 Luciferase Substances 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 101000705925 Homo sapiens Protein STPG4 Proteins 0.000 description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 description 8
- 108091035539 telomere Proteins 0.000 description 8
- 102000055501 telomere Human genes 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 241000124008 Mammalia Species 0.000 description 7
- 108091034117 Oligonucleotide Proteins 0.000 description 7
- 230000003833 cell viability Effects 0.000 description 7
- 238000003556 assay Methods 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 210000004962 mammalian cell Anatomy 0.000 description 6
- 210000003411 telomere Anatomy 0.000 description 6
- 108091081406 G-quadruplex Proteins 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 4
- 101000844866 Homo sapiens H/ACA ribonucleoprotein complex subunit DKC1 Proteins 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 210000005260 human cell Anatomy 0.000 description 4
- 230000000626 neurodegenerative effect Effects 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 238000003757 reverse transcription PCR Methods 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- 229940123582 Telomerase inhibitor Drugs 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 208000009356 dyskeratosis congenita Diseases 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 102000051771 human DKC1 Human genes 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000003277 telomerase inhibitor Substances 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 238000009010 Bradford assay Methods 0.000 description 2
- 108010069860 GSE24.2 peptide Proteins 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 102000042773 Small Nucleolar RNA Human genes 0.000 description 2
- 108020003224 Small Nucleolar RNA Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 208000025434 cerebellar degeneration Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 235000015220 hamburgers Nutrition 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 108010057210 telomerase RNA Proteins 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 101150028074 2 gene Proteins 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 101710128979 23 kDa piroplasm membrane protein Proteins 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 208000018240 Bone Marrow Failure disease Diseases 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 101100297347 Caenorhabditis elegans pgl-3 gene Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 241000219130 Cucurbita pepo subsp. pepo Species 0.000 description 1
- 235000003954 Cucurbita pepo var melopepo Nutrition 0.000 description 1
- 101150080917 DKC1 gene Proteins 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 101100016370 Danio rerio hsp90a.1 gene Proteins 0.000 description 1
- 101100285708 Dictyostelium discoideum hspD gene Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 206010016334 Feeling hot Diseases 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 101001087045 Homo sapiens Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN Proteins 0.000 description 1
- 101000626112 Homo sapiens Telomerase protein component 1 Proteins 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 101710177166 Phosphoprotein Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 235000000903 Ranunculus bulbosus Nutrition 0.000 description 1
- 240000005608 Ranunculus bulbosus Species 0.000 description 1
- 101710094326 Ras-related protein R-Ras Proteins 0.000 description 1
- 241000242739 Renilla Species 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 108010081734 Ribonucleoproteins Proteins 0.000 description 1
- 102000004389 Ribonucleoproteins Human genes 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 101100071627 Schizosaccharomyces pombe (strain 972 / ATCC 24843) swo1 gene Proteins 0.000 description 1
- 102100024553 Telomerase protein component 1 Human genes 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 101710157927 Translationally-controlled tumor protein Proteins 0.000 description 1
- 101710175870 Translationally-controlled tumor protein homolog Proteins 0.000 description 1
- 102100024180 Transmembrane emp24 domain-containing protein 10 Human genes 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- MGSKVZWGBWPBTF-UHFFFAOYSA-N aebsf Chemical compound NCCC1=CC=C(S(F)(=O)=O)C=C1 MGSKVZWGBWPBTF-UHFFFAOYSA-N 0.000 description 1
- -1 age Chemical class 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 231100000024 genotoxic Toxicity 0.000 description 1
- 230000001738 genotoxic effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920002704 polyhistidine Polymers 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 229940121649 protein inhibitor Drugs 0.000 description 1
- 239000012268 protein inhibitor Substances 0.000 description 1
- 108010049718 pseudouridine synthases Proteins 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- 102200015255 rs121912297 Human genes 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000009331 sowing Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- LSGOVYNHVSXFFJ-UHFFFAOYSA-N vanadate(3-) Chemical compound [O-][V]([O-])([O-])=O LSGOVYNHVSXFFJ-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Vascular Medicine (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
Priority Applications (12)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200502511A ES2325431B1 (es) | 2005-10-14 | 2005-10-14 | Secuencia de nucleotidos y peptidos gse 24.2 de la disquerina inductores de la actividad telomerasa, procedimiento de obtencion, composiciones terapeuticas y sus aplicaciones. |
| EP06849419A EP1947175B1 (en) | 2005-10-14 | 2006-10-11 | Sequence of nucleotides and peptides gse 24.2 of dyskerin, which can induce telomerase activity, method for obtaining same, therapeutic compositions and applications thereof |
| DK06849419.4T DK1947175T3 (da) | 2005-10-14 | 2006-10-11 | Sekvens af nukleotider og peptider GSE 24,2 af dyskerin, der kan fremkalde telomeraseaktivitet, fremgangsmåde til fremstilling deraf, terapeutiske sammensætninger og anvendelser deraf |
| JP2008535049A JP5560398B2 (ja) | 2005-10-14 | 2006-10-11 | テロメラーゼ活性を誘導するジスケリンのｇｓｅ２４．２ポリヌクレオチドおよびペプチドの配列、その取得方法、医薬組成物およびその使用方法 |
| ES06849419T ES2360238T3 (es) | 2005-10-14 | 2006-10-11 | Secuencias de nucleótidos y péptidos gse 24.2 de disquerina que puede inducir actividad de la telomerasa, procedimiento para obtener la misma, composiciones terapéuticas y aplicaciones de la misma. |
| CA002625981A CA2625981A1 (en) | 2005-10-14 | 2006-10-11 | Sequence of nucleotides and peptides gse 24.2 of dyskerin, which can induce telomerase activity, method for obtaining same, therapeutic compositions and applications thereof |
| PCT/ES2006/070152 WO2007090911A1 (es) | 2005-10-14 | 2006-10-11 | Secuencia de nucleótidos y péptidos gse 24.2 de la disquerina inductores de la actividad telomerasa, procedimiento de obtención, composiciones terapéuticas y sus aplicaciones |
| AT06849419T ATE469212T1 (de) | 2005-10-14 | 2006-10-11 | Sequenz von nukleotiden und peptiden gse 24.2 aus dyskerin zur herbeiführung von telomerase- aktivität, herstellungsverfahren dafür sowie therapeutische zusammensetzungen und anwendungen davon |
| DE602006014574T DE602006014574D1 (de) | 2005-10-14 | 2006-10-11 | Sequenz von nukleotiden und peptiden gse 24.2 aus dyskerin zur herbeiführung von telomerase-aktivität, herstellungsverfahren dafür sowie therapeutische zusammensetzungen und anwendungen davon |
| PT06849419T PT1947175E (pt) | 2005-10-14 | 2006-10-11 | Sequência de nucleótidos e de péptidos gse 24.2 da disquerina, que podem induzir a actividade da telomerase, método para os obter, composições terapêuticas e suas aplicações |
| US12/090,215 US9074194B2 (en) | 2005-10-14 | 2006-10-11 | Sequence of nucleotides and peptides GSE 24.2 of dyskerin, which can induce telomerase activity, method for obtaining same, therapeutic compositions and applications thereof |
| US14/740,890 US9587002B2 (en) | 2005-10-14 | 2015-06-16 | Sequence of nucleotides and peptides GSE 24.2 of dyskerin, which can induce telomerase activity, method for obtaining same, therapeutic compositions and applications thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200502511A ES2325431B1 (es) | 2005-10-14 | 2005-10-14 | Secuencia de nucleotidos y peptidos gse 24.2 de la disquerina inductores de la actividad telomerasa, procedimiento de obtencion, composiciones terapeuticas y sus aplicaciones. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ES2325431A1 ES2325431A1 (es) | 2009-09-03 |
| ES2325431B1 true ES2325431B1 (es) | 2010-06-28 |
Family
ID=38344881
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES200502511A Expired - Fee Related ES2325431B1 (es) | 2005-10-14 | 2005-10-14 | Secuencia de nucleotidos y peptidos gse 24.2 de la disquerina inductores de la actividad telomerasa, procedimiento de obtencion, composiciones terapeuticas y sus aplicaciones. |
| ES06849419T Active ES2360238T3 (es) | 2005-10-14 | 2006-10-11 | Secuencias de nucleótidos y péptidos gse 24.2 de disquerina que puede inducir actividad de la telomerasa, procedimiento para obtener la misma, composiciones terapéuticas y aplicaciones de la misma. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES06849419T Active ES2360238T3 (es) | 2005-10-14 | 2006-10-11 | Secuencias de nucleótidos y péptidos gse 24.2 de disquerina que puede inducir actividad de la telomerasa, procedimiento para obtener la misma, composiciones terapéuticas y aplicaciones de la misma. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US9074194B2 (enExample) |
| EP (1) | EP1947175B1 (enExample) |
| JP (1) | JP5560398B2 (enExample) |
| AT (1) | ATE469212T1 (enExample) |
| CA (1) | CA2625981A1 (enExample) |
| DE (1) | DE602006014574D1 (enExample) |
| DK (1) | DK1947175T3 (enExample) |
| ES (2) | ES2325431B1 (enExample) |
| PT (1) | PT1947175E (enExample) |
| WO (1) | WO2007090911A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2334736B1 (es) * | 2007-11-23 | 2011-02-02 | Consejo Superior De Investigaciones Cientificas (Titular Al 90%) | Uso de agentes inductores gse24.2 para la elaboracion de composiciones farmaceuticas para el tratamiento de enfermedades que cursan con senescencia celular. |
| WO2014122346A1 (es) * | 2013-02-05 | 2014-08-14 | Consejo Superior De Investigaciones Cientificas (Csic) | Bionanopartículas biodegradables para liberación del péptido gse24-2, procedimiento de obtención y utilización |
| WO2015059338A1 (es) | 2013-10-25 | 2015-04-30 | Consejo Superior De Investigaciones Científicas (Csic) | Péptidos derivados de gse24.2 para tratar enfermedades producidas por estrés oxidativo y daño al adn |
| WO2020223475A1 (en) * | 2019-05-02 | 2020-11-05 | Board Of Regents, The University Of Texas System | Methods and compositions involving tert activating therapies |
| ES2989543A1 (es) * | 2023-05-22 | 2024-11-26 | Alodia Farm S L U | Peptidos para su uso en la prevencion y/o tratamiento de radiodermitis |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999054449A2 (de) * | 1998-04-17 | 1999-10-28 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Dyskerin und dafür codierende dna-moleküle, diese enthaltende vektoren, antikörper gegen dyskerin und die verwendung dieser gegenstände |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5350836A (en) * | 1989-10-12 | 1994-09-27 | Ohio University | Growth hormone antagonists |
-
2005
- 2005-10-14 ES ES200502511A patent/ES2325431B1/es not_active Expired - Fee Related
-
2006
- 2006-10-11 JP JP2008535049A patent/JP5560398B2/ja not_active Expired - Fee Related
- 2006-10-11 EP EP06849419A patent/EP1947175B1/en active Active
- 2006-10-11 ES ES06849419T patent/ES2360238T3/es active Active
- 2006-10-11 DK DK06849419.4T patent/DK1947175T3/da active
- 2006-10-11 AT AT06849419T patent/ATE469212T1/de active
- 2006-10-11 DE DE602006014574T patent/DE602006014574D1/de active Active
- 2006-10-11 US US12/090,215 patent/US9074194B2/en not_active Expired - Fee Related
- 2006-10-11 PT PT06849419T patent/PT1947175E/pt unknown
- 2006-10-11 CA CA002625981A patent/CA2625981A1/en not_active Abandoned
- 2006-10-11 WO PCT/ES2006/070152 patent/WO2007090911A1/es not_active Ceased
-
2015
- 2015-06-16 US US14/740,890 patent/US9587002B2/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999054449A2 (de) * | 1998-04-17 | 1999-10-28 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Dyskerin und dafür codierende dna-moleküle, diese enthaltende vektoren, antikörper gegen dyskerin und die verwendung dieser gegenstände |
Non-Patent Citations (2)
| Title |
|---|
| KNIGHT, S.W., et al. "{}X-linked dyskeratosis congenita is predominantly caused by missense mutations in the DKC1 gene"{}. AM. J. HUM. GENET. 27.05.1999. Vol. 65, páginas 50-58, todo el documento. * |
| VULLIAMY, T.J., et al. "{}Dyskeratosis congenita caused by a 3' deletion: Germline and somatic mosaicism in a female carrier"{}. BLOOD. 15.08.1999. Vol. 94, n$^{o}$ 4, páginas 1254-1260, todo el documento. * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007090911A1 (es) | 2007-08-16 |
| US20150337022A1 (en) | 2015-11-26 |
| JP2009511036A (ja) | 2009-03-19 |
| EP1947175B1 (en) | 2010-05-26 |
| ES2325431A1 (es) | 2009-09-03 |
| PT1947175E (pt) | 2010-09-02 |
| ATE469212T1 (de) | 2010-06-15 |
| CA2625981A1 (en) | 2007-08-16 |
| JP5560398B2 (ja) | 2014-07-23 |
| DK1947175T3 (da) | 2010-09-27 |
| ES2360238T3 (es) | 2011-06-02 |
| DE602006014574D1 (de) | 2010-07-08 |
| US20090202503A1 (en) | 2009-08-13 |
| US9587002B2 (en) | 2017-03-07 |
| EP1947175A1 (en) | 2008-07-23 |
| US9074194B2 (en) | 2015-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chun et al. | Cytosolic Hsp60 is involved in the NF-κB-dependent survival of cancer cells via IKK regulation | |
| Won et al. | Human Noxin is an anti‐apoptotic protein in response to DNA damage of A549 non‐small cell lung carcinoma | |
| CN103800904A (zh) | Hat乙酰化启动子和其组合物在促进免疫原性中的用途 | |
| KR102252423B1 (ko) | 암 특이적 트랜스-스플라이싱 리보자임 및 이의 용도 | |
| US9587002B2 (en) | Sequence of nucleotides and peptides GSE 24.2 of dyskerin, which can induce telomerase activity, method for obtaining same, therapeutic compositions and applications thereof | |
| KR20170098931A (ko) | 뇌 질환을 치료하기 위한 방법 및 조성물 | |
| Shervington et al. | Glioma: what is the role of c-Myc, hsp90 and telomerase? | |
| Zheng et al. | Nanoparticle-mediated rhodopsin cDNA but not intron-containing DNA delivery causes transgene silencing in a rhodopsin knockout model | |
| ES2334736B1 (es) | Uso de agentes inductores gse24.2 para la elaboracion de composiciones farmaceuticas para el tratamiento de enfermedades que cursan con senescencia celular. | |
| Parkinson | Telomerase as a novel and potentially selective target for cancer chemotherapy | |
| Rapisarda et al. | Antiangiogenic agents and HIF-1 inhibitors meet at the crossroads | |
| WO2019052000A1 (zh) | 一种靶向STAT3信号通路miRNA及其制备方法和应用 | |
| Melman et al. | Gene therapy in the management of erectile dysfunction (ED): past, present, and future | |
| Perona Abellón et al. | Sequence of nucleotides and peptides GSE 24.2 of dyskerin, which can induce telomerase activity, method for obtaining same, therapeutic compositions and applications thereof | |
| US12194057B2 (en) | NXTAR-derived oligonucleotides and uses thereof | |
| KR101527749B1 (ko) | miR-186, miR-216b, miR-337-3p 및 miR-760 억제제를 유효성분으로 포함하는 세포 노화 예방 또는 치료용 조성물 | |
| NZ569075A (en) | Use of elF-5A to kill multiple myeloma cells | |
| KR100880850B1 (ko) | 고형암 세포에서 사이클로필린 ａ의 발현을 억제하는물질을 포함하는 시스플라틴에 대한 내성 억제용 약제학적조성물 및 그를 이용하여 고형암의 시스플라틴에 대한내성을 억제하는 방법 | |
| SÁNCHEZ PÉREZ | TELOMERASE ACTIVITY, METHOD FOR OBTAINING SAME, THERAPEUTIC COMPOSITIONS | |
| KR20230030063A (ko) | 암 특이적 트랜스-스플라이싱 리보자임과 키나아제 억제제를 포함하는 암 치료적 병용물 | |
| Le Francois | Mechanisms underlying thymidylate synthase regulation in human cells | |
| WO2008112701A2 (en) | G-substrate for the treatment and prevention of parkinson's disease | |
| KR20050098800A (ko) | 임포틴 α유전자 및/또는 재조합 ｐ５３ 유전자를 포함하는항암제 | |
| Young | Overcoming replicative senescence in human cells and tissues using telomerase gene therapy | |
| Yimam | Identification and characterization of primate P-glycoprotein |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EC2A | Search report published |
Date of ref document: 20090903 Kind code of ref document: A1 |
|
| FG2A | Definitive protection |
Ref document number: 2325431B1 Country of ref document: ES |
|
| FD2A | Announcement of lapse in spain |
Effective date: 20180809 |